• About
    • OUR LEADERSHIP
    • OUR CAB/SAB
  • Science and Technology
    • THERAPEUTIC POTENTIAL OF MSCs
    • OUR TECHNOLOGY PLATFORM
    • PUBLICATIONS
  • Pipeline
  • News
  • Careers
  • Contact
  • About
    • OUR LEADERSHIP
    • OUR CAB/SAB
  • Science and Technology
    • THERAPEUTIC POTENTIAL OF MSCs
    • OUR TECHNOLOGY PLATFORM
    • PUBLICATIONS
  • Pipeline
  • News
  • Careers
  • Contact

Archives

Monthly Archive for: "September, 2016"
By Payal Garg
In News
Posted September 15, 2016

Sentien CEO Brian Miller Featured on Front Page of BioWorld™ Today

Sentien Biotechnologies CEO Brian Miller was featured on the front page of BioWorld™ Today on September 15, 2016.  Mr. Miller participated on a Biopharm America panel discussing “How to [...]

 Read More
About
  • Our Leadership
  • Our CAB/SAB
  • Careers
Science and Technology
  • Therapeutic Potential of MSCs
  • Our Technology Platform
  • Pipeline
  • Publications
News
  • Press Releases
Contact Us

Sentien Biotechnologies, Inc.
99 Hayden Ave.
Building E, Suite 140
Lexington, MA 02421

Phone: +1-781-361-9031

Email: info@sentienbiotech.com

All Rights Reserved © 2017
Brian Miller, MS/MBA

Brian MillerMr. Miller has over 18 years of experience in the life science industry.  Mr. Miller has previously held the roles of Executive Director and Head, Corporate Development at FORMA Therapeutics, a clinical stage oncology company, and Head of Business Development – Asia Pacific for Quosa, Inc., a life science informatics company.  He began his biotech career at Eli Lilly and Company, where he led the identification, evaluation, and in-licensing of research informatics technologies in the Global External Research & Development group.  Brian received BA degrees in Chemistry and Business from Goshen College, an MS degree in Health Sciences from the Harvard-MIT Division of Health Sciences Technology, and an MBA from the MIT Sloan School of Management.

×
Biju Parekkadan, PhD

Biju ParekkadanDr. Parekkadan is an Assistant Professor of Bioengineering at Massachusetts General Hospital and is an affiliated faculty member of the Harvard Stem Cell Institute and the Broad Institute.  In 2012, he was recognized by Harvard Medical School with a Young Mentor of the Year Award and by the White House with a Presidential Early Career Award for Scientists and Engineers (PECASE), the highest honor given by the US government for early career investigators. His doctoral research generated the IP behind the formation of the company, and he leads the R&D of Sentien.  He received a B.S. in Biomedical Engineering from Rutgers University (2003) and a Ph.D. in Chemical and Medical Engineering from the Harvard-MIT Division of Health Sciences and Technology (2008).

×
Robert Deans, PhD

Dr. Deans is currently the Chief Scientific Officer of Rubius Therapeutics.  He has more than 25 years of experience in adult stem cell therapeutics which includes work with stem cells from bone marrow including both hematopoietic as well as mesenchymal stem cell populations.  He has previously served as the executive vice president at Athersys, Inc., vice president of research at Osiris Therapeutics, and director of research and development at Baxter Healthcare.

×
Martin Heidecker, PhD

Martin HeideckerDr. Heidecker joined the Boehringer Ingelheim Venture Fund in 2010 to invest in early innovative therapeutic life science companies. In October 2013, Martin established the US-office of BIVF in Cambridge, MA, where he is focusing on biotech seed-investments. He has 15 years of investing and commercial experience in both venture capital and global pharma companies. In addition to Sentien, he serves as board member of AMP Therapeutics in Leipzig, ArmaGen in Calabasas and 121bio in Cambridge.

×
Richard Ganz, MBA

Rich GanzMr. Ganz has been active in the healthcare industry for over 30 years.  He is currently principal of RGA Life Sciences, a life science consultancy based out of Wilmette, IL.  Formerly, Mr. Ganz was Chief Operating Officer of Piramal Critical Care, a global pharmaceutical company headquartered in Bethlehem, PA, President and Chief Executive Officer at Omnisonics Medical Technologies, President of the North American Renal Division for Baxter International, Inc., and a Divisional VP and General Manager of Vascular Products at Abbott Laboratories.

×
Johannes Fruehauf, MD, PhD

johannes-fruehauf_headshotDr. Fruehauf is the Co-Founder and General Partner of BioInnovation Capital.  He is also a founder of LabCentral, a launchpad for high-potential biotech startups, and serves as its president and executive director.  Prior to LabCentral, he founded Cambridge Biolabs, a contract research facility serving startup and virtual companies in Kendall Square.  Dr. Fruehauf is also a co-founder of ViThera Pharmaceuticals, Deltix and Cequent Pharmaceuticals, and an advisor or board member to numerous life sciences companies and non-profits. 

 

×
Giacomo Chiesi, MBA

Giacomo currently serves both as Managing Partner at Chiesi Ventures and the Head of Global Corporate Development at the Chiesi Group.

In his tenure with the Chiesi Group he has directly structured and executed deals with $2B in value ranging from sell-side to buy-side M&A, in- and out-licensing, and spin-outs. In 2014, he founded Chiesi Ventures as a joint venture with Pappas Capital.

Before going back to the Chiesi Group, Giacomo was a consultant with Bain & Co, where he led teams in a variety of assignments including due diligence, restructuring and strategy projects for consumer goods and IT companies in different countries. Previously he was with Accenture where he led large teams in outsourcing projects across Europe and US for clients in the transportation and retail business.

Giacomo earned a M.Sc. degree Magna cum Laude in Telecommunications Engineering from the University of Parma, Italy, and an MBA from the University of Chicago Booth School of Business with concentrations in Entrepreneurship and Finance. He currently serves as a Board Member or Observer on the Board of Chiesi, Chiesi USA, Aura Bioscience, Minoryx Therapeutics, Glycomine, Sentien Biotech and Palladio Biosciences. He also sits on the Advisory Board of Abingworth Capital Partners and Mercurio Capital Partners.

×
Bruce Littman, MD

Dr. Littman is President of Translational Medicine Associates, LLC, an independent consulting company serving customers in the areas of translational research, early clinical development planning and execution, risk assessment for early biotech and biomarker development. Previously, he spent 19 years at Pfizer, culminating in his role as Vice President and Global Head of Translational Medicine, and he is board certified in Internal Medicine and Rheumatology.

×
Herbert Lin, MD, PhD, FASN

Dr. Lin is Director of Translational Research in the division of Nephrology at Massachusetts General Hospital. He is board certified in Internal Medicine and Nephrology, and his research focuses on the role of TGF-Beta/BMP signaling pathways.  He is also the co-founder of FerruMax Pharmaceuticals, Inc., which is a clinical stage company developing a new treatment for anemia.

×
Joseph Bonventre, MD, PhD, FASN

Dr. Bonventre is the Robert H. Ebert Professor of Medicine at Harvard Medical School and Professor of Health Sciences and Technology at MIT. He is Director of the Renal Division of the Brigham and Women’s Hospital. His research focuses primarily on the study of kidney injury and repair and signal transduction, with a special emphasis on the role of inflammation, biomarkers and stem cells. He also currently Chairs the Kidney Group of the Harvard Stem Cell Initiative and is co-chair of the Stem Cell, Regenerative Medicine and Tissue Engineering Center of the Brigham and Women’s Hospital Research Institute and co-chair of the Technology in Medicine initiative at Brigham and Women’s, and in 2010-11 served as President of the American Society of Nephrology.

×
Declan Doogan, MD

Dr. Doogan is currently CEO of Portage Biotech, Inc, and a partner with Mediqventures, LTD. His career spans over 30 years in both major pharma and biotech, including roles of Senior Vice-President and Head of Worldwide Development at Pfizer, CMO and acting CEO of Amarin, and CMO of Prometheus Laboratories.

×
Robert Deans, PhD

Dr. Deans is currently the Chief Scientific Officer of Rubius Therapeutics.  He has more than 25 years of experience in adult stem cell therapeutics which includes work with stem cells from bone marrow including both hematopoietic as well as mesenchymal stem cell populations.  He previously served as the executive vice president at Athersys, Inc., vice president of research at Osiris Therapeutics, and director of research and development at Baxter Healthcare.

×
Declan Doogan, MD

Dr. Doogan is currently CEO of Portage Biotech, Inc, and a partner with Mediqventures, LTD. His career spans over 30 years in both major pharma and biotech, including roles of Senior Vice-President and Head of Worldwide Development at Pfizer, CMO and acting CEO of Amarin, and CMO of Prometheus Laboratories.

×
Pedro Huertas, MS, MD, PhD

Dr. Huertas has nearly 30 years of pharmaceutical industry experience in research and development, medical affairs and regulatory affairs in therapeutics for human genetic and metabolic diseases. Prior to joining Sentien, Dr. Huertas was Chief Medical Officer for Eloxx Pharmaceuticals, a company focused on rare and ultra-rare genetic diseases.  Prior experience includes clinically focused positions with big pharma (Pfizer, Genzyme), small biotech (ExSAR Corporation, Amicus Therapeutics, Novazyme), and cell therapy companies (Ocata, StemCells, Inc.).  Dr. Huertas is a graduate of Stanford University (MS, Biochemistry), Harvard University (PhD, Cell and Developmental Biology), Harvard Medical School (MD), and MIT Sloan School of Management (MS, Management). He also trained in Internal Medicine, Rheumatology, and Palliative Care at Massachusetts General Hospital.

×